Zealand Announces Collaboration with Eli Lilly

Article

Zealand will join efforts with Eli Lilly to design and develop therapeutic peptides for Type 2 diabetes and obesity.

Zealand Pharma, a biopharmaceutical company based in Copenhagen specializing in peptides, has formed a peptide drug R+D collaboration agreement with Eli Lilly.

Under the agreement, Zealand will collaborate with Eli Lilly in the design and development of peptide therapeutics for the treatment of Type 2 diabetes and obesity. The companies will share in the funding, risk, and reward of the program. Future expansion of the collaboration to additional drug targets and disease areas is possible. No financial terms of the agreement have been disclosed.

Source: Zealand Pharma

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
David Fairen-Jimenez
William K. Oh, MD
Eswar Iyer, Aikium Inc.
Leroy (Lee) Hood, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.